title: Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response.
abstract: BACKGROUND
  Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear.
  
  
  METHODS
  Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence.
  
  
  RESULTS
  Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed Class II HLA antibodies compared with 28% (Class I) and 15% (Class II) for those receiving leukoreduced blood and 36% (Class I) and 54% (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies.
  
  
  CONCLUSIONS
  These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.
authors.affiliation: Blood Systems Research Institute, San Francisco, California; Puget Sound Blood Center, Seattle, Washington; University of California, Davis, California; National Institutes of Health, Bethesda, Maryland; University of Southern California, Los Angeles, California; Children's National Medical Center, Washington, DC; Department of Laboratory Medicine, University of California, San Francisco, California; Department of Medicine, University of California, San Francisco, California; University of Washington School of Medicine, Seattle, Washington.
authors.forename: Rachael P
authors.initials: RP
authors.lastname: Jackman
authors.forename: Xutao
authors.initials: X
authors.lastname: Deng
authors.forename: Douglas
authors.initials: D
authors.lastname: Bolgiano
authors.forename: Garth H
authors.initials: GH
authors.lastname: Utter
authors.forename: Cathy
authors.initials: C
authors.lastname: Schechterly
authors.forename: Mila
authors.initials: M
authors.lastname: Lebedeva
authors.forename: Eva
authors.initials: E
authors.lastname: Operskalski
authors.forename: Naomi L
authors.initials: NL
authors.lastname: Luban
authors.forename: Harvey
authors.initials: H
authors.lastname: Alter
authors.forename: Michael P
authors.initials: MP
authors.lastname: Busch
authors.forename: Sherrill J
authors.initials: SJ
authors.lastname: Slichter
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Norris
mesh_terms: D000917:Antibody Formation / Q000502:physiology* / Q000528:radiation effects*; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D047589:Leukocyte Reduction Procedures; D008297:Male; D014466:Ultraviolet Rays
chemical_list: D015395:Histocompatibility Antigens Class I